Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Newsbot!
    Banned
    • Feb 2008
    • 1331

    PubMed: Profiling model T cell metagenomes with short reads.

    Syndicated from PubMed RSS Feeds

    Related Articles Profiling model T cell metagenomes with short reads.

    Bioinformatics. 2009 Jan 9;

    Authors: Warren RL, Nelson BH, Holt RA

    MOTIVATION: T cell receptor (TCR) diversity in peripheral blood has not yet been fully profiled with sequence level resolution. Each T cell clonotype expresses a unique receptor, generated by somatic recombination of TCR genes and the enormous potential for T cell diversity makes repertoire analysis challenging. We developed a sequencing approach and assembly software (immuno-SSAKE or iSSAKE) for profiling T cell metagenomes using short reads from the massively parallel sequencing platforms. RESULTS: Models of sequence diversity for the TCR beta-chain CDR3 region were built using empirical data and used to simulate, at random, distinct TCR clonotypes at 1-20 parts per million. Using simulated TCRbeta (sTCRbeta) sequences, we randomly created 20 million 36nt reads having 1%-2% random error, 20 million 42nt or 50nt reads having 1% random error and 20 million 36nt reads with 1% error modeled on real short read data. Reads aligning to the end of known TCR variable (V) genes and having consecutive unmatched bases in the adjacent CDR3 were used to seed iSSAKE de novo assemblies of CDR3. With assembled 36nt reads we detect over 51% and 63% of rare (1 ppm) clonotypes using a random or modeled error distribution, respectively. We detect over 99% of more abundant clonotypes (6 ppm or higher) using either error distribution. Longer reads improve sensitivity, with assembled 42nt and 50nt reads identifying 82.0% and 94.7% of rare 1 ppm clonotypes, respectively. Our approach illustrates the feasibility of complete profiling of the TCR repertoire using new massively parallel short read sequencing technology. AVAILABILITY: ftp://ftp.bcgsc.ca/supplementary/iSSAKE. CONTACT: [email protected] SUPPLEMENTARY INFORMATION: Supplementary methods and data available at Bioinformatics online and at ftp://ftp.bcgsc.ca/supplementary/iSSAKE.

    PMID: 19136549 [PubMed - as supplied by publisher]



    More...

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    Yesterday, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Yesterday, 11:10 AM
0 responses
9 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
30 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-09-2026, 10:04 AM
0 responses
41 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-08-2026, 10:08 AM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Working...